Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

Key Inclusion Criteria:

• Healthy males and females (not of childbearing potential) between the ages of 18 and 65 years
• Body weight between 50.0 kg and 95.0 kg
• Willing and able to comply with clinic visits and study-related procedures
• Provide signed informed consent

Key Exclusion Criteria:

• Donation or loss of approximately 400 mL or more of blood within 8 weeks prior to dosing, or plasma up to 14 days prior to dosing
• Hemoglobin not within normal limits
• Positive drug and alcohol screen test results at screening visits 1 and 2
• Low or elevated blood pressure and/or heart rate after 3 minutes resting in the seated position:
• Recent use (within 3 months prior to screening) of androgenic steroids
• Participation in any clinical research study that evaluated another investigational drug or therapy within 30 days or at least 5 half-lives, whichever is longer, of the investigational drug, prior to the screening visit
• Previous exposure to any biological therapeutic agent, except vaccines
• Known sensitivity to tamoxifen, doxycycline, or similar compounds (ie, tetracyclines)
• Pregnant or breastfeeding women, and women of childbearing potential
• Sexually active men who are unwilling to practice adequate contraception during the study